A detailed history of New Edge Advisors, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 1 shares of ALNY stock, worth $244. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 995 99.9%
Holding current value
$244
Previous $241,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $232,407 - $285,287
-994 Reduced 99.9%
1 $0
Q2 2024

Aug 15, 2024

BUY
$143.31 - $247.0 $140,013 - $241,319
977 Added 5427.78%
995 $241,000
Q1 2024

May 14, 2024

BUY
$146.51 - $198.2 $2,051 - $2,774
14 Added 350.0%
18 $2,000
Q1 2023

May 12, 2023

SELL
$182.66 - $235.53 $10,959 - $14,131
-60 Reduced 93.75%
4 $0
Q4 2022

Feb 14, 2023

BUY
$185.53 - $241.31 $11,873 - $15,443
64 New
64 $15,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.1B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.